Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After aSAH
| Status: | Completed |
|---|---|
| Conditions: | Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - 99 |
| Updated: | 2/2/2018 |
| Start Date: | May 1, 2010 |
| End Date: | January 1, 2017 |
Comparison of Short Duration Levetiracetam to Extended Course Levetiracetam for Seizure Prophylaxis Following Subarachnoid Hemorrhage
Our primary objective is to compare two treatment options for prevention of seizures
following a subarachnoid hemorrhage and determine if a short-course regimen of levetiracetam
is as efficacious in the prevention of in-hospital seizures when compared to an extended
course.
following a subarachnoid hemorrhage and determine if a short-course regimen of levetiracetam
is as efficacious in the prevention of in-hospital seizures when compared to an extended
course.
This is a prospective, single-center, randomized, controlled trial. Patients admitted with
spontaneous SAH (and meet enrollment criteria) will be randomized to either levetiracetam
1000 mg twice daily for 3 days or levetiracetam 1000mg twice daily until hospital discharge.
spontaneous SAH (and meet enrollment criteria) will be randomized to either levetiracetam
1000 mg twice daily for 3 days or levetiracetam 1000mg twice daily until hospital discharge.
Inclusion Criteria:
1. Age >18 years of age
2. Diagnosis of spontaneous SAH
Exclusion Criteria:
1. SAH secondary to trauma or arteriovenous malformation
2. Early death (defined as death within 3 days of presentation)
3. Known allergy to levetiracetam
4. Know seizure history on chronic AEDs
5. Pregnancy
6. Current incarceration
We found this trial at
1
site
Click here to add this to my saved trials
